Somnus Therapeutics is developing a timed-release formulation of zaleplon, a GABA agonist that is currently approved for short-term difficulty in falling asleep. According to company, its version of the drug is expected to offer patients an initial two hours of drug-free delta sleep, followed by the controlled release of a short-acting active ingredient, which may allow people to awaken more refreshed and alert.
135 Route 202/206
Bedminster, NJ 07921
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights